NCHR Testimony on Omadacycline for Skin Infections and Pneumonia

August 8, 2018. If omadacycline is no better than some drugs on the market, and may be less safe or less effective for older patients, those with more serious infections, and patients with diabetes and lung disease, it is important to conduct further studies to know whether they should be excluded from the indication or not.

Read More »

NCHR Testimony of TIRF REMS

August 3, 2018. TIRFs provide important options for cancer patients dealing with pain. However, we all know that they carry very serious risks and that’s why we need REMS that protect patients’ these risks.  These REMS are not working as well as the should to protect patients and need to be approved.

Read More »

NCHR Testimony on Nucala for Eosinophilic COPD

July 26, 2018. New products must provide a real and clinically meaningful benefit, not just a hope that the treatment works. Unfortunately, the clinical trial data presented today do not provide substantial evidence that mepolizumab [Nucala] provides this benefit for patients with COPD and high eosinophil counts.

Read More »

Letter to Members of Congress Opposing the “Accurate Labels Act”

July 11, 2018. We urge you to oppose this dangerous family-unfriendly legislation that: undermines the health of the American public; eliminates states’ existing ability to inform their citizens about the ingredients of products and the dangers that they may pose; and keeps Americans in the dark about the products they bring into their homes.

Read More »